Abstract: The transistor comprises first and second source/drain electrodes formed in a semiconductor film by N-doped and P-doped areas, respectively. A polarization voltage is applied between the two source/drain electrodes in order to impose to the P-doped electrode a potential higher than that of the N-doped electrode. The transistor comprises first and second devices for generating a potential barrier in the semiconductor film. The two potential barriers are opposed to the passage of the charge carriers emitted by the first and second source/drain electrodes, respectively. The two potential barriers are shifted with respect to an axis connecting the two source/drain electrodes. The two devices for generating a potential barrier are configured to generate a potential barrier having a variable amplitude and it are electrically connected to the gate and to the counter electrode.

Abstract: The present invention is directed to a process for the preparation of an aqueous dispersion of coacervates having a core-shell structure, the core (a) being an inorganic particle being anionic or cationic and the shell (b) being a copolymer wherein said copolymer comprises at least two parts, A and B, part A being cationic if particle (a) is anionic, and anionic if particle (a) is cationic, and part B being neutral in pH conditions of said dispersion. More particularly, the invention is directed to treating compositions comprising that aqueous dispersion of coacervates delivering antifouling, water sheeting, antisoiling, anti-adhesion, adhesion, anti-deposition, and/or anti-UV properties onto all kinds of surfaces.

Abstract: The invention relates to trisubstituted or tetrasubstituted imidazo[4,5b]pyridines, to their uses as well as to a process for manufacturing them. The compounds of the invention are imidazo[4,5b]pyridines. The first general synthesis of 3,5,7 imidazo[4,5b]pyridines is disclosed in the description. The invention founds application, in particular, in the pharmaceutical field.

Abstract: A method for conducting a neutralization assay for the determination of the titer of antibodies in a sample is provided which is an improvement over existing neutralization assays because the sensitivity of the reporter gene assay to determine neutralization is increased by the use of a “one time use” cell line transformed with a reporter gene construct. The titer is determined for antibodies specific for a predetermined target molecule that activates the signal transduction activity of a cell surface protein or a pattern recognition receptor or are specific for an antagonist for the predetermined target molecule.

Abstract: Disclosed is a method of detecting at least one oscillatory fault in at least one positional slaving chain for at least one airfoil of an aircraft. The method involves estimating a reference position of the airfoil in the absence of a fault, and calculating a residual value based on the difference between the estimated reference position and the actual position measured by at least one sensor. The calculated residual value is compared with at least one predetermined threshold value to determine the number of successive and alternating overshoots of the predetermined threshold value by the residual value, and oscillatory fault is determined based on the determined number.

Abstract: An adsorption method includes the step of adsorbing hybrid particles from a colloidal dispersion of such particles at an interface between the dispersion and a second phase, said hybrid particles comprising: (a) a nanoscale inorganic core having an outer surface, and (b) an organic layer disposed on at least a portion of the surface of the inorganic core and comprising one or more phosphonates according to structure (I): wherein: R1 and R2 are each independently H, or a (C1-C20)hydrocarbon group, R3 is a divalent (C1-C20)hydrocarbon group, R4 and R5 are each independently H or (C1-C2)alkyl, provided that R4 differs from R5, R6 is H or a (C1-C30)hydrocarbon group, m and n are each independently integers of from 0 to about 200, provided that the sum of m+n is at least 1.

Abstract: Accordingly, the invention provides constructs in which the nucleic acids encoding Plasmodium falciparum MSP4 and MSP5, and the resulting polypeptides, have been modified. More particularly, this invention provides constructs encoding recombinant MSP4 and MSP5 polypeptides, which are expressed as soluble, secreted polypeptides in a baculovirus-insect cell expression system. It was surprisingly found that the recombinant polypeptides contain an EGF-like domain at the C-terminus that is properly folded in the polypeptide.

Abstract: The present invention provides a cell for use in a one-step cell-based assay for an extracellular ligand (e.g., I FN?) that initiates a ligand-specific signal at the nucleus of the cell and for neutralizing antibodies against the extracellular ligand. The cell-based one-step assay allows both the extracellular ligand concentration and the neutralizing antibody titer to be quantified in a single sample (e.g., serum) without the need for sample dilution and addition of exogenous extracellular ligand.

Abstract: The present invention relates to the field of acoustic wave devices, and particularly to that of transducers capable of operating at very high frequencies, from a few hundred MHz to several gigahertz, and its subject is more particularly an interface acoustic wave device including at least two substrates and a layer of ferroelectric material, the latter being contained between a first electrode and a second electrode and having first positive-polarization domains and second negative-polarization domains, the first and second domains being alternated, wherein the assembly constituted by the first electrode, the layer of ferroelectric material, and the second electrode is contained between a first substrate and a second substrate.

Abstract: A method for visualizing an active synapse wherein said method comprises: (a) exposing cells forming the active synapse to a biomarker comprising at least fragment C of tetanus toxin and a reporter protein; and (b) visualizing the biomarker; wherein the accumulation of the biomarker into dendritic spines of the cells allows visualization of an active synapse. Also, a method for screening molecules capable of modulating synapse activity is provided. A kit useful for the early diagnosis of neurodegenerative disease comprises a biomarker comprising at least fragment C of tetanus toxin and a reporter protein.

Abstract: A hybrid protein (GFP-TTC) comprising the non-toxic proteolytic C fragment of tetanus toxin fused to green fluorescent protein was used to analyze the functional synaptic organization of neural networks. When injected intramuscularly in vivo, the GFP-TTC hybrid protein binds to tetanus neurotoxin receptors and clusters very rapidly to the active neuromuscular junction. Membrane traffic by GFP-TTC at the pre-synaptic level of the neuromuscular junction is strongly and rapidly influenced by exogenously co-injecting neurotrophic factors, such as BDNF, NT-4, and GDNF, but not by NGF, NT-3, and CNTF. The membrane traffic, directly detected using GFP-TTC in vivo, permits methods of analyzing synaptic functioning as well as methods of modulating neuronal transport using neurotrophic factors and agonists or antagonists thereof.

Abstract: The invention concerns multiparticulate galenic formulations for oral administration and designed for colon targeted delivery of active principles selected from the group comprising enzymes capable of inactivating macrolides and the like, enzymes capable of inactivating quinolones and ?-lactamases.

Abstract: A composite suitable as a charge-storing material for electrochemical capacitors contains carbon nanotubes and a carbonaceous materiel. The carbonaceous material is the carbonization residue of a biopolymer or seaweed rich in heteroatoms. Wherein the carbonization residue of the biopolymer or seaweed is electrically conductive and has a heteroatom content as detected by XPS of at least 6%.

Abstract: The present invention relates to a commercializable cell and to a gene reporter assay method and a kit which use this cell to determine the presence and/or the level of a molecule that activates signal transduction activity of a cell surface protein. This cell is treated in such a manner that it will have a sufficiently long shelf life for its intended purpose, whereupon at the end of its useful shelf life or at the end of its use, i.e., in an assay, the cell undergoes cellular death.

Abstract: A method for conducting a neutralization assay for the determination of the titer of antibodies in a sample is provided which is an improvement over existing neutralization assays because the sensitivity of the reporter gene assay to determine neutralization is increased by the use of a “one time use” cell line transformed with a reporter gene construct. The titer is determined for antibodies specific for a predetermined target molecule that activates the signal transduction activity of a cell surface protein or a pattern recognition receptor or are specific for an antagonist for the predetermined target molecule.

Abstract: The present invention relates to a commercializable cell and to a gene reporter assay method and a kit which use this cell to determine the presence and/or the level of a molecule that activates signal transduction activity of a cell surface protein. This cell is treated in such a manner that it will have a sufficiently long shelf life for its intended purpose, whereupon at the end of its useful shelf life or at the end of its use, i.e., in an assay, the cell undergoes cellular death.

Abstract: The present invention relates to a commercializable cell and to a gene reporter assay method and a kit which use this cell to determine the presence and/or the level of a molecule that activates signal transduction activity of a cell surface protein. This cell is treated in such a manner that it will have a sufficiently long shelf life for its intended purpose, whereupon at the end of its useful shelf life or at the end of its use, i.e., in an assay, the cell undergoes cellular death.

Abstract: A method and apparatus for reducing a selected tonal noise generated by an axial flow fan operating in a non-uniform flow by locating at least one obstruction in the non-uniform flow such that the at least one obstruction generates a noise that is out of phase with the selected tonal noise. The noise generated by the at least one obstruction interferes with the selected tonal noise, thus reducing the selected tonal noise. It is also contemplated to use additional obstructions to reduce other tonal noises generated by the axial flow fan.

Abstract: The present invention provides an implantable device for semiautomatic suturing using a surgical thread, the suturing enabling biological and/or artificial tissues to be united, the device comprising: blocking means enabling two strands of the thread of a suture to be connected together in a blocking zone; a bearing element having a bearing surface for bearing against the tissues to be sutured together; and controlled tensioning means for applying controlled tensioning to said thread, and suitable, after the two strands of said thread have been blocked together using said blocking means, for exerting a tension at a first predetermined tension value, with the junction between said bearing element and said blocking zone of the device being provided by said controlled tensioning means.

Abstract: The invention relates to methods of introducing a heterologous DNA sequence into a mouse embryonic stem cell wherein the DNA sequence is inserted by homologous recombination into a villin gene/I-SceI hybrid by creating a double strand break with I-SceI meganuclease. Subsequently, the mouse embryonic stem cells can be used to generate a transgenic mouse comprising the heterologous DNA sequence. Additionally, the methods can be used for gene replacement in ovo where a mouse oocyte containing a villin gene/I-SceI hybrid within its genome exists or is first generated. More generally, the methods can be used for the targeted insertion of a heterologous DNA sequence into any cell containing a villin gene/I-SceI hybrid sequence within its genome.